Table 1 Demographic and clinical characteristics according to CAV1 genotype (rs4730751)
From: Donor caveolin 1 (CAV1) genetic polymorphism influences graft function after renal transplantation
CAV1 genotype ( n = 475) | |||
|---|---|---|---|
AA | AC | CC | |
n = 36 (7.6%) | n = 194 (40.8%) | n = 245 (33.2%) | |
BMI (kg/m2) | 23.4 ± 4.0 | 24.4 ± 4.6 | 24.1 ± 4.3 |
Age at transplantation (years) | 44.0 ± 14.4 | 47.8 ± 12.5 | 47.5 ± 12.3 |
Sex of the recipient (M/F) | 69.4%/30.6% | 66.0%/34.0% | 60.0%/40.0% |
Age of donor (years) | 41.9 ± 15.8 | 45.8 ± 14.9 | 45.4 ± 15.1 |
Sex of the donor (M/F) | 68.6%/31.4% | 70.3%/29.7% | 69.0%/31.0% |
Initial nephropathy | |||
Glomerulonephritis | 31.4% | 33.3% | 32.1% |
Interstitial nephropathy | 14.3% | 17.4% | 21.0% |
Vascular and diabetic nephropathy | 14.3% | 14.4% | 8.3% |
Hereditary nephropathy | 17.1% | 15.9% | 21.0% |
Other | 8.6% | 8.2% | 5.6% |
Undetermined | 14.3% | 10.8% | 11.9% |
Immunization (HLA antibody >30%) | 2.8% | 10.9% | 9.8% |
Cold ischemia time (h) | 20.8 ± 6.9 | 21.3 ± 6.9 | 20.8 ± 6.7 |
HLA mismatch (A/B/DR) | 3.6 ± 1.4 | 3.4 ± 1.9 | 3.4 ± 1.3 |
Delayed graft function | 12.9% | 25.7% | 20.3% |
Acute rejection | 8.6% | 15.6% | 9.8% |
NODAT | 17.3% | 15.7% | 20.6% |
CMV disease | 5.6% | 10.8% | 9.8% |
Proteinuria (year 2) | 10% | 17.3% | 19.4% |
Proteinuria (year 5) | 35.7% | 21.3% | 13.8% |
Anti CD-25 antibody induction | 41.4% | 44.4% | 48.2% |
ATG induction | 58.6% | 55.6% | 51.8% |
Immunosuppressive therapy (year 1) | |||
Steroids therapy (%) | 40 | 36 | 42 |
Mycophenolate daily dose (g/day) | 1.23 ± 0.26 | 1.40 ± 0.51 | 1.31 ± 0.60 |
Tacrolimus daily dose (mg/kg/day) | 0.08 ± 0.03 | 0.08 ± 0.04 | 0.09 ± 0.04 |
Tacrolimus trough blood level (ng/mL) | 7.36 ± 3.40 | 8.40 ± 3.29 | 7.69 ± 3.30 |